Thurnher M, Rieser C, Höltl L, Papesh C, Ramoner R, Bartsch G
Department of Urology, University of Innsbruck, Austria.
Urol Int. 1998;61(2):67-71. doi: 10.1159/000030291.
Dendritic cells potently stimulate antigen-specific immune responses and recent data indicate that they are also capable of eliciting antitumor immune responses. We are performing a pilot study which tests the safety and efficacy of antigen-loaded, cultured blood dendritic cells in patients with metastatic renal cell carcinoma. Dendritic cells are simultaneously pulsed with lysate from autologous tumor cells and with the immunogenic protein keyhole limpet hemocyanin. During the pulse, the cells are activated with a combination of tumor necrosis factor-alpha and prostaglandin E2. Patients receive 5-10 X 10(6) dendritic cells per intravenous infusion and up to six infusions at monthly intervals. The first results demonstrate that this treatment modality is very well tolerated and can be associated with strong immunological and clinical responses. The present article discusses the importance of dendritic cell maturation and the role of helper antigens in dendritic cell-based immunotherapy.
树突状细胞能有力地刺激抗原特异性免疫反应，近期数据表明它们也能够引发抗肿瘤免疫反应。我们正在进行一项试点研究，以测试负载抗原的培养血液树突状细胞对转移性肾细胞癌患者的安全性和有效性。树突状细胞同时用来自自体肿瘤细胞的裂解物和免疫原性蛋白钥孔戚血蓝蛋白进行脉冲处理。在脉冲处理过程中，细胞用肿瘤坏死因子-α和前列腺素E2的组合进行激活。患者每次静脉输注接受5 - 10×10⁶个树突状细胞，每月间隔最多输注6次。初步结果表明，这种治疗方式耐受性良好，并且可能与强烈的免疫和临床反应相关。本文讨论了树突状细胞成熟的重要性以及辅助抗原在基于树突状细胞的免疫治疗中的作用。
